Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 6
1997 5
1998 4
2000 1
2002 7
2003 8
2004 7
2005 15
2006 49
2007 74
2008 100
2009 103
2010 85
2011 87
2012 130
2013 108
2014 90
2015 56
2016 60
2017 75
2018 95
2019 109
2020 133
2021 167
2022 149
2023 101
2024 44

Text availability

Article attribute

Article type

Publication date

Search Results

1,403 results

Results by year

Filters applied: . Clear all
Page 1
Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.
Mori K, Mostafaei H, Sari Motlagh R, Pradere B, Quhal F, Laukhtina E, Schuettfort VM, Kramer G, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF. Mori K, et al. Among authors: karakiewicz pi. BJU Int. 2022 Apr;129(4):423-433. doi: 10.1111/bju.15507. Epub 2021 Jul 21. BJU Int. 2022. PMID: 34171173 Free PMC article. Review.
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI. Wenzel M, et al. Among authors: karakiewicz pi. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):139-148. doi: 10.1038/s41391-021-00395-4. Epub 2021 May 30. Prostate Cancer Prostatic Dis. 2022. PMID: 34054128 Free PMC article. Review.
Reply by Authors.
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Wenzel M, et al. Among authors: karakiewicz pi. J Urol. 2021 Jul;206(1):79. doi: 10.1097/JU.0000000000001695.03. Epub 2021 Apr 6. J Urol. 2021. PMID: 33820427 No abstract available.
Editorial Comment.
Karakiewicz PI. Karakiewicz PI. J Urol. 2019 Sep;202(3):531. doi: 10.1097/01.JU.0000569232.25218.7c. Epub 2019 Aug 8. J Urol. 2019. PMID: 31192750 No abstract available.
Intermediate-risk Prostate Cancer: Stratification and Management.
Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, Klotz L, Montironi R, Nguyen PL, D'Amico AV. Preisser F, et al. Among authors: karakiewicz pi. Eur Urol Oncol. 2020 Jun;3(3):270-280. doi: 10.1016/j.euo.2020.03.002. Epub 2020 Apr 14. Eur Urol Oncol. 2020. PMID: 32303478 Review.
IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time.
Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Panunzio A, Tappero S, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, Shariat SF, Graefen M, Tilki D, Antonelli A, Kosiba M, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Hoeh B, et al. Among authors: karakiewicz pi. Semin Oncol. 2022 Oct;49(5):394-399. doi: 10.1053/j.seminoncol.2022.10.001. Epub 2022 Oct 23. Semin Oncol. 2022. PMID: 36333148 Review.
1,403 results